Asia stocks track rally in S&P futures; confused on Syria
April 9, 2018Novartis bets big on gene therapy with $8.7 billion AveXis deal
April 9, 2018Novartis shells out $8.7 billion to buy AveXis
at
ZURICH (Reuters) – Novartis said on Monday it plans to buy AveXis for $218 per share in a cash deal totaling $8.7 billion as the Swiss drugmaker adds a company whose top drug hopeful, for spinal muscular atrophy, has U.S. breakthrough therapy designation.
Powered by WPeMatico
